Fig 1: FGL1 expression inhibits the proliferation of CD8+ TRM cells in vitro (A) PBMCs were cultured in the presence of IL-15 (50 ng/mL) for 3 days and then with TGF-β (50 ng/mL) for an additional 3 days to activate CD8+ TRM cells. The expression of the markers of CD8+ TRM cells and other CD8+ T-cell subpopulations was determined. (B) FGL1 (100 nM) was added to the cultures, and the percentage of CD8+ TRM cells was detected after activation. (C) Expression of CD8+ TRM cell surface molecules, such as PD-1, LAG3, TIM-3, and CTLA-4, was detected after activation. (D) Expression of CD8+ TRM cell cytokines, such as IFN-γ, IL-2, and TNF-α, as well as GZMB, was detected after activation. (E) Expression of CD8+ TRM cell transcription factors, such as Runx3, Eomes, T-bet, and TOX, was detected after activation. (A–E) A paired t-test. Bars represent mean ± SEM. FGL1, fibrinogen-like protein 1; GZMB, granzyme B; PBMC, peripheral blood mononuclear cell. (*P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001). n.s. means not siginificant.
Fig 2: IL-15 promotes cutaneous T-cell lymphoma (CTCL) cell proliferation in vitro. (A) Proliferation of Hut78 cells treated with different cytokines at 50 ng/ml. Each condition was tested in technical triplicate. Data represent mean±s.e.m. Two-way ANOVA with Dunnett's multiple comparisons test, comparing with PBS at day 3. **P<0.01. (B) Expression of cytokine receptors in Hut78 cells by quantitative PCR (qPCR). qPCR assays were set up in technical duplicates. Data represent mean±s.e.m. (C) Analysis of JUN and JUNB gene expression by qPCR in Hut78 cells treated with IL-15 for 24 h. Gene expression was normalized to GAPDH. qPCR assays were set up in technical triplicates. Data represent mean±s.e.m. Ordinary one-way ANOVA with Dunnett's multiple comparisons test, comparing with PBS. **P<0.01, ***P<0.001. (D) Western blot analysis of Hut78 cells treated with 2 μM JNK-IN-8, 50 ng/ml IL-15 or their combination for 24 h. Representative results from one of two independent experiments are shown.
Fig 3: In vitro validation of immune activation by enTnpBa.a Schematic workflow for in vitro validation of enTnpBa-mediated immune activation. The protein levels of CXCL9 (b), IFN-γ (c), and IL-15 (d) in the lysates and culture supernatants (SNs) of HEK293T cells transfected with the ImmunAct plasmid were assessed via Western blotting. Secreted cytokine levels in the SN were also measured by ELISA. The control group consisted of HEK293T cells transfected with ImmunAct containing nontargeting (NT) enωRNA spacers, with the corresponding cell lysates and supernatants analyzed. Each experiment was performed with n = 3 independent biological replicates. e CD8⁺ T-cell migration was evaluated via a transwell assay using culture supernatants (SNs) collected from HEK293T cells transfected with ImmunAct (termed SN-ImmunAct). Data are derived from n = 3 independent biological replicates. Representative fluorescence microscopy images of CFSE-labeled T cells that migrated to the lower chamber. The right panel shows the quantification of T cells in the lower chamber. Scale bar = 100 μm. f Flow cytometry analysis showing representative plots (g) and quantification (h) of granzyme B (GZMB) expression in CD8⁺ T cells treated with SN-NT or SN-ImmunAct. Each condition was analyzed in n = 3 independent biological replicates. Flow cytometry analysis of tumor cell death in UM-UC-3mCherry (g) and T24mCherry (h) bladder cancer cells pretreated with AAV-NT or AAV-ImmunAct, followed by coculture with activated human CD8⁺ T cells. Data are derived from n = 3 independent biological replicates per condition. Representative fluorescence images (i) and quantification (j) of cell death in patient-derived bladder cancer organoids treated with AAV-NT or AAV-ImmunAct, followed by coculture with autologous PBMC-derived T cells from the same patient. Organoid cell death was assessed by measuring the MFI of NucRed Dead 647 (red fluorescence) within the outlined organoid region. Scale bar = 100 μm. The data are presented as means ± SD. A dot represents a biological replicate (n = 3). Unpaired two-tailed Student’s t tests. Source data are provided as a Source data file. Figure 6a were created in BioRender. Lu, J. (2026) https://BioRender.com/p92mphp.
Fig 4: Workflow of the study.Schematic representation of the workflow of the study, including TnpB engineering (left panel), gene regulation tool development (middle panel), and therapeutic evaluation in tumor models (right panel). Multiple rounds of engineering yielded a truncated ωRNA and optimal TnpB variants, collectively referred to as enhanced TnpB (enTnpB). Three functional gene regulation tools based on enTnpB were developed: an endogenous gene activator (enTnpBa), a gene editor (enTnpB-GE), and an adenine base editor (enTnpB-ABE). For therapeutic evaluation, enTnpBa with ωRNA arrays targeting three immune activators, CXCL9, IFN-γ, and IL-15, was packaged into a single adeno-associated virus (AAV) vector, named AAV-ImmunAct. The efficacy of AAV-ImmunAct was validated by both in vitro assays and in vivo cancer models. This figure were created in BioRender. Lu, J. (2026) https://BioRender.com/4yvrpxm.
Fig 5: Development of an enTnpB-based gene editor (GE) and adenine base editor (ABE).a Schematic of enTnpB-derived gene editors: GE#WT (WT ωRNA + WT TnpB), GE#1 (enωRNA + WT TnpB), and GE#2 (enωRNA + enTnpB). WT wild type. b Indel efficiencies of GE#WT, GE#1, and GE#2. A dot represents one independent biological replicate (n = 3). c Distribution of deletion events relative to the sequence surrounding the protospacer. The top bar shows the indel positions. Each box represents one nucleotide, and the blue shading intensity indicates the fraction (%) of deletions at each position. d Indel efficiencies of GE#WT and GE#1 across thirteen additional loci. A dot represents one independent biological replicate (n = 3). e Off-target analysis of GE#1 by GUIDE-seq at three target sites. f Schematic of enTnpB-based adenine base editors (ABEs): ABE#WT (WT ωRNA + WT TnpB), ABE#1 (enωRNA + WT TnpB), and ABE#2 (enωRNA + enTnpB). WT wild type. g A-to-G conversion efficiencies at three target sites for ABE#WT, ABE#1, and ABE#2. Results are based on n = 3 independent biological replicates per condition. h Validation of A-to-G conversion efficiencies of ABE#2 across ten target sites, including five sites each for IFN-γ and IL-15 (named #1–#5). Each site was evaluated in n = 3 independent biological replicates. i Editing window analysis of ABE#4, integrating data from ten target sequences (five each from IFN-γ and IL-15). The top row indicates adenine positions within the protospacer, with the first base at the 5′ end defined as position 1. The blue shading intensity of each box represents the proportion of A-to-G conversion events at that position relative to the total A-to-G conversion events across all positions for the same target sequence. The data are presented as means ± SD. A dot represents a biological replicate (n = 3). Source data are provided as a Source data file. Figure 5a, f were created in BioRender. Lu, J. (2026) https://BioRender.com/ekfc5yw; https://BioRender.com/vecr6to.
Supplier Page from Abcam for Anti-IL-15 antibody [3A3]